During trading today, the Health Care sector (XLV) showed little change while the S&P 500 fell 0.6%.

The ETF is up 0.7% from its 50-day moving average and 5.4% from its 200-day moving average. As a proxy for the sector, the ETF tracked closer to the overall market today than over the past month. Entering today's trading, XLV was up 1.2% over the last thirty trading days. The S&P 500, in comparison, went up -1.9%.

Human Genome (HGSI) rose 97.6% to close at $14.17, cross its 50-day moving average of $7.81 and 200-day moving average of $9.14. Atrion Corporation (ATRI) declined 0.9% to close at $213.12, moving below its 50-day moving average of $212.81 and 200-day moving average of $224.44.

Dendreon Corporation (DNDN) rose 11.7% to close at $10.03, approaching its 50-day moving average of $10.33. It has also moved closer to its 200-day moving average of $11.03.

Achillion Pharmaceuticals (ACHN) was one of the sector's big losers, as its price dropped 12.6% (-$1.20) to close at $8.30. 6.3 million shares of the stock moved. The stock traded between $7.16 and $8.40. The stock has been on a downward trajectory over the last two months, sliding $2.38 (-22.3%) from a price of $10.68 on February 21, 2012.

Gilead (GILD) was a major gainer in the sector, rising 12.1% (+$5.64) to close at $52.25 with 35.9 million shares moving. The stock traded in a range of $51.60 to $54.75. The stock has been on an upward trajectory over the last two months, climbing $7.56 (16.9%) from a price of $44.69 on February 21, 2012.

Merrimack Pharmaceuticals (MACK) hit a new 52-week high today, reaching $9 to top the previous high of $8.08.